News
We send the latest information from SMC Laboratories.
Introduction of chronic kidney disease mice models
I am writing you today to share some information on our Chronic kidney disease (CKD) models. CKD is a condition that is characterized by abnormalities in the structure or function of the kidneys. It is a global public health problem and causes a rising incidence and prevalence of kidney failure with poor outcomes. However,…
Introduction of NASH model with high clinical correlation
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Around the world, the prevalence of NAFLD has now increased to 30%, and it is expected to continue to increase [Younossi Z et al., Hepatology. 2023]. One of the risks of NAFLD is its ability to progress to other…
Introduction of bleomycin-induced SSc-ILD model
Today, we would like to introduce a more clinically correlative model in which skin and lung fibrosis develop simultaneously. Systemic scleroderma is a progressive, rare disease that causes fibrosis not only in the skin but also in tissues throughout the body, including the heart, lungs and kidneys. Pulmonary disease is a complication that has…
Introduction of positive control drug for kidney fibrosis mouse model
Today, we would like to introduce an established positive control – an ALK5 inhibitor – for our Unilateral Ureteral Obstruction (UUO)-induced renal fibrosis model. This ALK5 inhibitor has an inhibitory effect on the TGF-beta/ALK5 signaling pathway, which plays a central role in renal fibrosis. Due to its antifibrotic abilities, we have established the ALK5 inhibitor…
Introduction of our experiences in histopathological analyses for IPF
Today, we present some new histopathological data from our bleomycin-induced pulmonary fibrosis model, which is a clinically representative mouse model that can be used to conduct drug efficacy studies for idiopathic pulmonary fibrosis (IPF). Histological endpoints are necessary in order to accurately assess and understand the pathological changes that occur in the target tissue…
Introduction of STAM™ model for pre-clinical studies for liver cancer
Today, we give you a brief introduction to our proprietary NASH-HCC model (STAM™ model). The STAM™ model was originally developed as a NASH model, but with a 100% incidence of hepatocellular carcinoma (HCC) as early as 20 weeks of age, it is also an excellent platform for oncology research and therapeutic development. The model…
Introducing our new skin disease model: Imiquimod (IMQ)-induced psoriasis model
We are pleased to announce that we have expanded our preclinical model lineup by including the “Imiquimod (IMQ)-induced dermatitis model” for psoriasis. Psoriasis is a refractory skin disease that is caused by both genetic and environmental factors. It causes chronic inflammation characterized by the clinical appearance of erythema and scaling of the skin….
Introduction of our Primary sclerosing cholangitis (PSC) mice model
Today, I would like to give you a brief introduction into primary sclerosing cholangitis (PSC), as well as our 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine (DDC) mouse model. PSC is a rare, chronic cholestatic liver disease characterized by biliary inflammation that develops into fibrosis and causes intrahepatic and/or extrahepatic bile duct strictures.These strictures impede bile flow within the ducts…
Introducing our Idiopathic Pulmonary Fibrosis (IPF) mouse model
The outbreak of COVID-19 causes a lot of complications and long-term harm to the patient, especially severe pulmonary fibrosis. We offer the Idiopathic Pulmonary Fibrosis (IPF) mouse model as a potential model for the development of therapeutics for lung fibrosis, and many of our customers have used this model through our introduction of its usefulness….
Potential NASH biomarker in NASH-HCC model
We would like to introduce the data for a serological marker from our NASH model (STAM™ model). Hepatocellular ballooning is a key finding distinguishing NASH from simple steatosis in terms of NASH diagnosis. CK-18 (cytokeratin 18) is known as one of the promising non-invasive biomarkers and was also recommended at the AASLD-FDA joint workshop because…